This is a 78-week single arm, multi-center, Phase 1 study to evaluate the safety, tolerability, cellular kinetics, and biomarker changes in C-peptide over time of GNTI-122, an investigational cell therapy manufactured from a participant's own blood…
- Investigator
- Brittany S Bruggeman
- Status
- Accepting Candidates
- Ages
- 18 Years - 55 Years
- Sexes
- All